Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lymphoma, Hodgkin lymphoma, child
Stage/Subtype:  stage III childhood Hodgkin lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 34 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment
Age: 18 and younger
Trial IDs: AHOD1331, NCI-2014-01223, NCT02166463
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868
Conventional and Regulatory T Cells in Treating Patients with Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607
Gemcitabine Hydrochloride, Clofarabine, and Busulfan before Donor Stem Cell Transplant in Treating Patients with Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 65
Trial IDs: 2012-0506, NCI-2012-02055, NCT01701986
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 6 months to less than 18 years
Trial IDs: 3475-051, NCI-2015-00528, 2014-002950-38, NCT02332668
A Single-Arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 30 and under
Trial IDs: GO29664, NCI-2015-01687, 2014-004697-41, NCT02541604
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed by Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancy or Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 0108M06725, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Immune Therapy in Treating Patients with Epstein-Barr Virus Lymphoproliferative Disorders or Epstein-Barr Virus-Associated Malignancies
Status: Active
Phase: Phase II
Type: Diagnostic, Treatment
Age: any age
Trial IDs: 11-130, NCI-2012-00594, NCT01498484
Donor Progenitor Cell and Natural Kill Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HAPNK1, NCI-2013-00609, NCT01807611
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low or Intermediate-Risk Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: H-30993, NCI-2013-01346, TXCH-HD-12A, NCT01858922
Safety Study of Cord Blood Units for Stem Cell Transplants
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients with Stage IIB-IVB Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and under
Trial IDs: HLHR13, NCI-2013-01123, NCT01920932
Nivolumab and Brentuximab Vedotin in Treating Older Patients with Untreated Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: RU051505I, NCI-2016-00468, NCT02758717
Autologous or Donor Cytotoxic T-Cells in Treating Patients With Epstein-Barr Virus-Positive Lymphoma, Lymphoepithelioma, or Lymphoproliferative Disorder
Status: Active
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: H-17946, NCI-2012-00654, TGFb, NCT00368082
Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes in Treating Patients With Newly Diagnosed or Recurrent Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: CAR CD30, NCI-2012-00640, H-26617, NCT01192464
Laboratory-Treated T Lymphocytes in Treating Patients With Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: H-27721, NCI-2012-01078, CART CD30, NCT01316146
T-Lymphocytes in Treating Patients with Active or Relapsed Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: BCM H 27471, NCI-2012-00680, CDR0000724621, H-27471-TACTAL, NCT01556269, 9101, NCT01333046
Donor Cytotoxic T-Lymphocytes in Treating Patients With Relapsed Epstein-Barr Virus-Associated Diseases
Status: Active
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: MALTED, NCI-2012-01079, H-28361, NCT01447056
Modified T-Cells in Treating Patients With Epstein-Barr Virus Positive Lymphoma.
Status: Active
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: H-29617, NCI-2013-01016, GRALE, NCT01555892
Start Over